Fluorizon - Molecular Radiolabeling Service

Fluorizon’s Molecular Radiolabeling Services

Fluorizon provides radiolabeling and preclinical imaging services to international biotech and pharmaceutical companies. Fluorizon’s unique radiolabeling technologies allows molecules to be rapidly and reliably radiolabeled. Molecular radiolabeling allows customers to gain unique insights into how their molecules perform in cellular assays or in small animal models using PET imaging. Fluorizon provides data that can be used accelerate and de-risk drug development pipelines.

Diagnostic Medical Imaging

Work at the Institute for Radiopharmaceutical Cancer Research

[borlabs-cookie id="youtube" type="content-blocker"] [/borlabs-cookie]

Positron emission tomography (PET) imaging is a non-invasive medical imaging technique used in combination with magnetic resonance imaging (MRI) or single-photon emission computed tomography (SPECT) in hospitals for the diagnosis of a number of clinical disorders. PET imaging is commonly used in cancer diagnostics, where the size and spread of the cancer is visualized.

Radiopharmaceuticals (radiolabeled molecules) are required for PET imaging experiments, and provide high resolution PET images where the pharmacokinetic and pharmacodynamic (PK/PD) pathways of the radiopharmaceutical can be visualized in real-time. Radiopharmaceuticals are radioactive molecules which must be rapidly prepared using specialized equipment and infrastructure prior to a PET imaging experiment.

Radiopharmaceuticals for Drug Development

PET imaging experiments may be used as an invaluable methodology to support drug development. In vitro and in vivo experiments using radiopharmaceuticals provide information concerning a drug candidate’s absorption, distribution, metabolism and excretion (ADME). PET images may also be used to determine drug-target interaction and blood brain barrier (BBB) penetration. Radiopharmaceuticals used for biodistribution studies are currently the gold standard approach in the analysis of the pharmacokinetics and the quantification of relative tissue concentrations.

Learn more about the Department of Medical Radiochemistry at HZDR

What we offer

Molecular Radiolabeling: We can transform molecules into radiopharmaceuticals with a variety of radionuclides depending on the desired application. Radionuclides including copper-64 ([⁶⁴Cu]), fluorine-18 ([¹⁸F], gallium-68 ([⁶⁸Ga]) and iodine-123 ([¹²³I]).
In vitro Assays: Real-time binding experiments using radiopharmaceuticals on live cells can be used to determine the binding mechanism, affinity and kinetics.
In vivo Experiments: Following in vitro validation, PET or SPECT imaging of radiopharmaceuticals using small animal models may be performed.

Discuss your requirements with us!

Fluorizon is a future spin-off company from Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstraße 400, 01328 Dresden

mail: austin.craig@fluorizon.com